.
MergerLinks Header Logo

New Deal


Announced

The Eczacıbaşı Group to acquire Gensenta from Amgen for $135m.

Financials

Edit Data
Transaction Value£110m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

Friendly

Single Bidder

Majority

Acquisition

Pending

Domestic

Pharmaceuticals

pharmaceutical products

Turkey

Synopsis

Edit

The Eczacıbaşı Group, a Turkish industrial group, agreed to acquire Gensenta, a manufacturer of pharmaceutical products, from Amgen, a biotechnology-based human therapeutics services, for $135m. “As a company that aspires to being a pioneer of modern, high quality and healthy living, we will expand our healthcare activities both in Turkey and international markets with innovative products and a wide product portfolio in different treatment areas. This acquisition fuels our growth by adding local production capabilities in pharmaceuticals, biosimilar products, and active ingredients to our investment portfolio as well as export competency," Bülent Eczacıbaşı, Eczacıbaşı Chairperson.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US